rct
    2015
    High Quality

    A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

    Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Ortiz RV, Jensen CB, Wilding JP

    Published in New England Journal of Medicine

    Key Findings

    Liraglutide 3.0 mg produced 8.4 kg weight loss versus 2.8 kg with placebo, with significant reductions in hunger and craving scores.

    Conclusions

    GLP-1 receptor agonism is the most effective pharmacological approach to excessive appetite.

    Limitations

    Industry-funded, high gastrointestinal adverse event rate.

    Outcomes Measured

    Weight Loss Support

    Liraglutide 3.0 mg produced 8.4 kg weight loss versus 2.8 kg with placebo.

    Related Health Concerns

    Excessive Appetite

    Study Details

    Year:2015
    Sample Size:3,731
    Duration:56 weeks
    Quality Score:9/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.